Irinotecan Injection

DRUG2 trials

Sponsors

Chinese Academy of Medical Sciences, Shanghai JMT-Bio Inc.

Conditions

Esophageal Squamous Cell CarcinomaStomach Cancer

Phase 2

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Chinese Academy of Medical SciencesEsophageal Squamous Cell Carcinoma

Start: 2018-07-31End: 2021-03-28Target: 45Updated: 2020-02-11

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

RecruitingNCT05427383

Shanghai JMT-Bio Inc.Stomach Cancer

Start: 2022-04-07End: 2026-11-30Target: 286Updated: 2023-12-19

Related Papers

PRELIMINARY SAFETY, EFFICACY AND PHARMACOKINETICS (PK) RESULTS OF KN026 (A HER2 BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED SOLID TUMOR PATIENTS WITH HER2 EXPRESSION

Antibody Therapeutics2023-07-01

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

Cancer Communications2020-12-01134 citations

Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.

Journal of Clinical Oncology2019-05-2012 citations